RE: GEN AI26 Sep 2024 09:34
Number of ordinary shares of £0.00425 each ("Shares") for which Admission is being sought 17,517,461
The Shares are and will remain freely transferable and have no restrictions as to transfer placed on them.
The issue price of the new Shares: £0.39 pence (the "Fundraising Price").
No Shares are or will be held in treasury.
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
Capital to be raised on Admission: £1.75 million
Anticipated market capitalisation on Admission £6.83 million (at the Fundraising Price)
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
75.52%
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:
N/A
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):
Lord David Lindsay Willetts (Independent Non-Executive Chairman)
Melissa Mariel Cruz Calderon (Chief Executive Officer)
Kevin Fitzpatrick (Chief Financial Officer)
Dr. David Michael Gann (Independent Non-Executive Director)
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known
On Admission
Shareholder
Tekcapital Europe Limited(1) 11,050,769 63.08%
Clifford Gross(2) 1,200,000 6.85%
Selwyn Lloyd(3) 360,000 2.06%
1) Tekcapital Europe Limited is a wholly owned subsidiary of Tekcapital Plc, from which GenIP was spun-out. Tekcapital Europe Limited will be locked-in for 12 months from Admission.
(2) Clifford Gross is Chief Executive Officer of Tekcapital Plc who will also be locked-in for 12 months from Admission.
(3) Selwyn Lloyd is the Chief Technology Officer of GenIP who will also be locked-in for 12 months from Admission.